Salesforce for Life Sciences: CRM Strategy for Pharma and Biotech

Salesforce has been making a serious play for life sciences CRM for the better part of a decade, and the momentum is real. The FDA’s digital health push, the commercial model shift away from fee-for-service toward outcomes-based contracting, and Veeva’s decision to move off the Salesforce platform and build its own cloud have all accelerated the conversation. Life sciences companies that locked into Veeva CRM five years ago are now asking hard questions about what comes next.

This is a practical overview of where Salesforce stands in life sciences, what it does well, where gaps remain, and how to think about CRM strategy in an environment where the commercial model is changing faster than most CRM implementations can keep up.

Why Salesforce Became the Dominant Platform

Salesforce didn’t win in life sciences by accident. Three structural factors made it the default.

First, the breadth of the platform. HCP engagement is a sales motion, but modern pharma commercial teams also need patient services, medical affairs, market access, and clinical operations on connected data. Salesforce is one of the few platforms that can span all of those functions without requiring separate vendor contracts. Sales Cloud, Service Cloud, Health Cloud, and the Life Sciences Cloud all sit on a single data model.

Second, the Veeva disruption. Veeva CRM was built on top of Salesforce’s platform — essentially a managed package. In 2022, Veeva announced its intent to migrate its CRM product off Salesforce and onto Vault, its own proprietary platform, by 2030. That decision forced every Veeva CRM customer to evaluate alternatives. Some will follow Veeva to Vault CRM. Others are evaluating Salesforce Life Sciences Cloud as a direct replacement. This is a live migration conversation happening at dozens of major pharma companies right now.

Third, the data model consolidation pressure. Pharma and biotech companies running separate instances of Veeva, Salesforce, SAP, and five other point solutions have accumulated a data fragmentation problem that limits their ability to personalize HCP engagement, measure channel mix effectiveness, or comply with aggregate spend reporting requirements. Salesforce’s pitch — one platform, one data model, configurable for any commercial function — is genuinely compelling compared to the alternative.

Life Sciences Cloud: What It Actually Is

Salesforce Life Sciences Cloud (formerly positioned as a competitor to Veeva CRM) is a purpose-built commercial platform for pharmaceutical, biotech, and medical device companies. It’s not a separate product in the way that Marketing Cloud or Commerce Cloud are separate — it’s a configuration layer and managed package that sits on top of Sales Cloud and Health Cloud, with pre-built objects and workflows for life sciences-specific use cases.

Key capabilities included in Life Sciences Cloud:

• HCP and HCO management — pre-built Person Account model for healthcare professionals and healthcare organizations, with relationship mapping between HCPs and accounts
• Call planning and routing — territory management, aligned to geographic or account-based segmentation
• Sample management — electronic sample lot tracking and compliance workflows
• Closed-loop marketing (CLM) — approved content delivery and rep-detailing functionality
• Aggregate spend tracking — Sunshine Act / transparency reporting data capture natively tied to HCP records
• Medical inquiry management — routing and logging of unsolicited medical information requests

What Life Sciences Cloud does not include natively is Veeva Vault integration (though Salesforce has published APIs), clinical trial data models, or a replacement for Veeva’s content management capabilities. For companies that rely heavily on Vault for regulatory content, the CRM transition and the content management question are separate problems.

Key Use Cases by Function

HCP Engagement and Field Force Effectiveness

The bread-and-butter use case for life sciences CRM is managing the field sales force’s interactions with healthcare professionals. In Salesforce, this means tracking call activity, digital interactions, sample drops, speaker programs, and other touchpoints against HCP records — and using that engagement data to segment and prioritize accounts.

The differentiator in Salesforce over legacy systems is the ability to connect HCP engagement data to prescribing behavior (via third-party data integrations like IQVIA or Symphony Health), then run that combined dataset through AI models (Einstein) to surface next best action recommendations at the rep level. This closed loop — prescribing data in, engagement data out, AI in between — is where Salesforce’s broader platform advantage becomes tangible.

Key Account Management

For specialty pharma and biologics where a small number of IDNs, GPOs, and health system accounts drive the majority of volume, key account management (KAM) is a distinct commercial discipline. Salesforce’s Account hierarchy, combined with Health Cloud’s care team and relationship mapping capabilities, supports the complex multi-stakeholder account structures that KAM requires.

A properly implemented KAM module in Salesforce tracks decision-maker relationships across pharmacy, formulary, medical, and executive contacts within a single health system account — and connects field activity, contract status, and engagement history in one view. This is substantially more capable than what most life sciences companies have today, where KAM data lives in a combination of Veeva, Excel, and institutional memory.

Medical Affairs

Medical Science Liaisons (MSLs) operate under different commercial compliance rules than sales reps — they can engage in broader scientific exchange, including off-label discussion in certain contexts, but their interactions must be scrupulously logged. Salesforce supports this with a separate MSL activity record type, configurable interaction logging, and the ability to tie medical inquiries to the appropriate HCP record and response documentation.

The compliance architecture matters here. MSL interactions cannot be attributed to sales rep performance metrics, and the system needs to enforce those boundaries at the data model level, not just through training. Salesforce’s permission model and record-level sharing rules make this configurable in ways that many legacy medical affairs systems cannot match.

Commercial Operations and Forecasting

Field force sizing, territory alignment, and quota-setting are upstream decisions that feed into CRM configuration. Salesforce doesn’t replace dedicated territory management tools (companies like Javelin or Veeva Align handle the optimization algorithms), but it can ingest the output of those tools and maintain alignment data as the source of truth for rep assignments and account ownership.

21 CFR Part 11 Considerations

If any part of your Salesforce implementation touches GxP processes — meaning the data or records could be subject to FDA inspection — you have a validation obligation. For commercial CRM, the most common GxP-adjacent processes are sample management (subject to Title 21 regulations), adverse event (AE) reporting capture, and medical affairs interaction logging where the records feed into regulatory submissions.

Most commercial CRM activity (HCP call logs, marketing campaign data, sales performance data) does not require 21 CFR Part 11 validation, because those records aren’t part of a submission and aren’t FDA-inspected. Pharma companies sometimes over-validate their commercial systems because of internal caution, which adds significant cost without reducing regulatory risk.

Where Part 11 validation is genuinely required, Salesforce satisfies several requirements natively: audit trail (Field History Tracking), access controls (permission sets and profiles), and electronic signature workflows (Salesforce’s DocuSign integration or OmniStudio-based signature capture). Gaps exist in the area of automated audit trail completeness — Salesforce’s native Field History Tracking has limits on which fields can be tracked and how long history is retained. Validated implementations typically address this with third-party audit trail tools or custom logging architecture.

Salesforce vs. Veeva: How to Actually Evaluate

The comparison is murkier than it used to be because Veeva Vault CRM is not yet fully deployed at scale, and Life Sciences Cloud has closed meaningful gaps in the last 24 months.

Choose Salesforce Life Sciences Cloud if: your commercial team is mid-sized (50–500 reps), you need tight integration with your Salesforce-based patient services or market access operations, you want to avoid a second CRM migration in 5–7 years when Veeva completes its platform transition, or you’re a biotech that doesn’t yet have a legacy Veeva contract to protect.

Choose Veeva if: you have a large, established global field force already running on Veeva CRM with deep integration into Veeva Vault for regulatory content, your organization has invested heavily in Veeva’s data and analytics products (Veeva Nitro, Veeva Pulse), and you have strong internal Veeva expertise. The switching cost from Veeva at scale is real — data models, training, integrations, and business processes are all embedded.

What neither vendor will tell you: the honest comparison is not between the two CRM products as they exist today, but between the migration paths. If you’re on Veeva CRM today, you have a migration ahead of you regardless — either to Vault CRM or to Salesforce. The question is which destination better serves your commercial model in 2030.

Commercial Model Shifts: Fee-for-Value and Outcomes-Based Contracting

The shift from volume-based to outcomes-based contracting is one of the most consequential changes in pharmaceutical commercial strategy, and CRM sits at the center of it.

Under fee-for-value and outcomes-based contracts (OBCs), manufacturers agree to rebates or price adjustments tied to patient outcomes — treatment adherence, lab value improvement, hospitalization reduction. Administering those contracts requires data: patient-level claims data, outcomes measurements, and payer-reported performance against agreed metrics.

Salesforce supports OBC administration through Health Cloud’s contract and care gap functionality, combined with data ingestion from claims clearinghouses. The CRM becomes not just a record of commercial activity but a platform for managing the contractual obligations that flow from new commercial models. This is a meaningful strategic advantage over Veeva’s product set, which has historically been built around the traditional rep-detailing model.

Companies implementing Salesforce with OBC in scope typically need a data integration layer (MuleSoft or a third-party ETL) to bring in claims data, a Health Cloud implementation for patient program management, and custom contract object configuration to model the specific terms of each payer agreement. Plan for 18–24 months to implement this at an enterprise level.

Starting Points and Timelines

For a commercial launch (new product, new field force standing up from scratch), a foundational Life Sciences Cloud implementation covering HCP management, territory alignment, call reporting, and sample management takes 6–9 months with an experienced SI. Budget $250K–$500K for implementation, depending on integration complexity.

For a Veeva replacement or expansion in an existing commercial organization, the timeline extends to 12–18 months due to data migration complexity, change management with an existing field force, and the need to run parallel systems during transition. Budget $400K–$800K for the implementation program, excluding license costs.

Life Sciences Cloud licensing starts at approximately $300/user/month for the commercial package, with additional modules (advanced analytics, OBC capabilities) priced separately.

---

Estarei is a boutique Salesforce consulting firm built by ex-Salesforce employees, with deep experience in Life Sciences Cloud, Health Cloud, and regulated industry implementations. If you’re evaluating Salesforce for your commercial operations or planning a Veeva transition, book a free consultation.